Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,126.06
(
1.20%
)
US TECH 100
25,958.80
(
1.33%
)
Dow Jones
49,447.43
(
1.88%
)
Brent Oil
92.80
(
4.43%
)
Bitcoin
73,886.17
(
-2.45%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: volgoat post# 259899

Saturday, 03/26/2016 2:26:13 PM

Saturday, March 26, 2016 2:26:13 PM

Post# of 347009

PPHM sold 5m shares at .40c to pay NCCN $2 million



I am very skeptical now and any PPHM investor should be curious when such claims as your above quote and do not provide any links to back it up.

Volgoat, you state this as fact and many that read it may think it is fact.... can you provide the links that led you to this conclusion?

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote